CO5560591A2 - Vacunas de adn optimizadas por el codon vih-gag - Google Patents

Vacunas de adn optimizadas por el codon vih-gag

Info

Publication number
CO5560591A2
CO5560591A2 CO04025208A CO04025208A CO5560591A2 CO 5560591 A2 CO5560591 A2 CO 5560591A2 CO 04025208 A CO04025208 A CO 04025208A CO 04025208 A CO04025208 A CO 04025208A CO 5560591 A2 CO5560591 A2 CO 5560591A2
Authority
CO
Colombia
Prior art keywords
gag
nef
truncated
optimized codon
hiv
Prior art date
Application number
CO04025208A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Beaton
Peter Franz Ertl
Gerald Wayne Gough
Andrew Lear
John Philip Tite
Wely Catherine Ann Van
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2001/004207 external-priority patent/WO2002024225A1/en
Priority claimed from GB0129604A external-priority patent/GB0129604D0/en
Priority claimed from GB0206462A external-priority patent/GB0206462D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO5560591A2 publication Critical patent/CO5560591A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CO04025208A 2001-09-20 2004-03-17 Vacunas de adn optimizadas por el codon vih-gag CO5560591A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2001/004207 WO2002024225A1 (en) 2000-09-20 2001-09-20 Use of immidazoquinolinamines as adjuvants in dna vaccination
GB0129604A GB0129604D0 (en) 2001-12-11 2001-12-11 Novel compounds
GB0206462A GB0206462D0 (en) 2002-03-19 2002-03-19 Vaccines

Publications (1)

Publication Number Publication Date
CO5560591A2 true CO5560591A2 (es) 2005-09-30

Family

ID=27256076

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04025208A CO5560591A2 (es) 2001-09-20 2004-03-17 Vacunas de adn optimizadas por el codon vih-gag

Country Status (16)

Country Link
US (2) US20070015721A1 (enExample)
EP (2) EP1427826B1 (enExample)
JP (1) JP4601956B2 (enExample)
CN (1) CN100392085C (enExample)
AR (1) AR036566A1 (enExample)
AU (1) AU2002362368B2 (enExample)
BR (1) BR0212619A (enExample)
CA (1) CA2461056A1 (enExample)
CO (1) CO5560591A2 (enExample)
HU (1) HUP0402259A3 (enExample)
IL (1) IL160809A0 (enExample)
MX (1) MXPA04002631A (enExample)
NO (1) NO331826B1 (enExample)
NZ (1) NZ531814A (enExample)
PL (1) PL207168B1 (enExample)
WO (1) WO2003025003A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487486B1 (en) * 2002-03-19 2009-01-14 PowderJect Research Limited Imidazoquinolineamines as adjuvants in hiv dna vaccination
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
GB2406336A (en) * 2003-09-24 2005-03-30 Oxxon Pharmaccines Ltd HIV Pharmaccines
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
DE102004049223A1 (de) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
AU2012201827B2 (en) * 2005-05-12 2014-09-04 Glaxo Group Limited Vaccine composition
CA2608316A1 (en) * 2005-05-12 2006-11-16 Glaxo Group Limited Vaccine composition
WO2008133663A2 (en) * 2006-11-30 2008-11-06 Government Of The United States Of America, As Represented By The Secretary, Codon modified immunogenic compositions and methods of use
GB0700914D0 (en) * 2007-01-18 2007-02-28 Animal Health Inst Polynucleotides and uses thereof
HUE031411T2 (en) 2007-03-02 2017-07-28 Glaxosmithkline Biologicals Sa New Methods and Preparations
US20090035360A1 (en) 2007-05-24 2009-02-05 Dominique Ingrid Lemoine Lyophilised antigen composition
WO2009092113A2 (en) * 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
EP2485759A4 (en) * 2009-10-09 2013-07-24 Univ New York METHOD, AGENTS AND PEPTIDES FOR GENERATING A BORN IMMUNE RESPONSE IN HIV VACCINATION
BRPI0914507A2 (pt) * 2009-12-23 2012-04-10 Fundacao Oswaldo Cruz vacina para lentivìrus baseada em vìrus recombinante vacinal da febre amarela
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
TR201802741T4 (tr) 2010-05-14 2018-03-21 Univ Oregon Health & Science Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları.
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
AU2014225886B2 (en) 2013-03-05 2020-04-16 Oregon Health & Science University Cytomegalovirus vectors enabling control of T cell targeting
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
CN113528466B (zh) 2014-07-16 2024-12-24 俄勒冈健康与科学大学 包含外源抗原的人巨细胞病毒
MA40783A (fr) * 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
SG11201706454VA (en) 2015-02-10 2017-09-28 Univ Oregon Health & Science Methods and compositions useful in generating non canonical cd8+ t cell responses
EP3350178B1 (en) 2015-09-14 2021-10-20 Pfizer Inc. Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors
CN108474003A (zh) 2015-11-20 2018-08-31 俄勒冈健康与科学大学 包含微小rna识别元件的cmv载体
BR112019007982A2 (pt) 2016-10-18 2019-07-02 Univ Oregon Health & Science vetores de citomegalovírus elicitando células t restringidas por moléculas do complexo de histocompatibilidade e principal
EP4058058A1 (en) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosage regimens for vaccines

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
ATE162219T1 (de) 1989-11-16 1998-01-15 Univ Duke Transformation von tierischen hautzellen mit hilfe von partikeln
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5583035A (en) * 1992-12-07 1996-12-10 Bayer Aktiengesellschaft HIV antisense expression vectors
US5654186A (en) 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
WO1995019799A1 (en) 1994-01-21 1995-07-27 Agracetus, Inc. Gas driven gene delivery instrument
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US5786464C1 (en) * 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
WO1997031115A2 (en) * 1996-02-22 1997-08-28 Merck & Co., Inc. Synthetic hiv genes
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
AU7332198A (en) * 1997-03-06 1998-09-22 Klaus Uberla Lentivirus based vector and vector system
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
EP1980617A1 (en) * 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
WO2000039304A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7332588B1 (en) * 1999-11-16 2008-02-19 Geneart Ag Genome of the HIV-1 inter-subtype (C/B) and use thereof
EP1242441A4 (en) * 1999-12-17 2004-04-14 Merck & Co Inc CODON OPTIMIZED HIV-1 NEF AND MODIFIED HIV-1 NEF EXPRESSING POLYNUCLEOTID VACCINE
US6656706B2 (en) * 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
WO2001047955A2 (en) * 1999-12-23 2001-07-05 Medical Research Council Improvements in or relating to immune responses to hiv
EP1156112B1 (en) * 2000-05-18 2006-03-01 Geneart GmbH Synthetic gagpol genes and their uses
WO2002032943A2 (en) * 2000-08-14 2002-04-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization

Also Published As

Publication number Publication date
HUP0402259A2 (hu) 2005-01-28
PL207168B1 (pl) 2010-11-30
JP4601956B2 (ja) 2010-12-22
EP1427826B1 (en) 2011-04-20
CN100392085C (zh) 2008-06-04
AU2002362368B2 (en) 2006-09-21
WO2003025003A3 (en) 2003-12-04
IL160809A0 (en) 2004-08-31
HUP0402259A3 (en) 2010-01-28
US20070015721A1 (en) 2007-01-18
CN1606624A (zh) 2005-04-13
MXPA04002631A (es) 2004-07-08
BR0212619A (pt) 2004-08-17
AR036566A1 (es) 2004-09-15
NO20041157L (no) 2004-05-19
NO331826B1 (no) 2012-04-16
WO2003025003A2 (en) 2003-03-27
NZ531814A (en) 2005-10-28
EP2322626A1 (en) 2011-05-18
EP1427826A2 (en) 2004-06-16
US20090203144A1 (en) 2009-08-13
CA2461056A1 (en) 2003-03-27
PL370359A1 (en) 2005-05-16
JP2005511019A (ja) 2005-04-28

Similar Documents

Publication Publication Date Title
CO5560591A2 (es) Vacunas de adn optimizadas por el codon vih-gag
MY145614A (en) Vaccine
Cho et al. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques
Silvera et al. Outcome of simian-human immunodeficiency virus strain 89.6 p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein
CO4600706A1 (es) Genes sinteticos del vih
ES2150897T3 (es) Procedimiento de fabricacion recombinante de las proteinas derivadas de hiv-2 y cultivo celular que expresa proteinas de hiv-2.
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
Voss et al. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine
NO992369L (no) Poxvirusbaserte ekspresjonsvektorer inneholdende heterologe innslag avledet fra lentivirus
DK33190A (da) Hiv-3 retrovirus og anvendelse heraf
ZA200107072B (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV.
Polacino et al. Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines
ES2069742T3 (es) Proteina de la capsida del calicivirus felino y secuencia nucleotida.
TW200502245A (en) Vaccine
ES292573Y (es) Autoclave de esterilizacion por medio de un gas o de una mezcla de gas-vapor.
DK0831899T3 (da) Rekombinant koppevirus-calicivirus-præparater og anvendelser
ANDERSON et al. The Genetics
EP0440207A3 (en) Expression of hiv1 and hiv2 polypeptides and use thereof
US20090076245A1 (en) HIV-1 Subtype Isolate Regulatory/Accessory Genes, and Modification and Derivatives Thereof
PE20000759A1 (es) Gen de la citocroma oxidasa de hidroquinona del tipo bd
MY131949A (en) Vaccines
Iglesias et al. Chimeric proteins containing HIV-1 T cell epitopes: Expression in E. coli, purification and induction of antibodies in mice
WO2004027066A3 (fr) Protéine recombinante chimérique et diagnostic in vitro du hiv
DK1511767T3 (da) Oprenset polypeptid, isolerede nukleinsyrer, som koder for polypeptidet, vektorer og anvendelse deraf
GB0325011D0 (en) HIV pharmaccines

Legal Events

Date Code Title Description
FC Application refused